Cargando…
CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
Programmed death‐ligand 1 (PD‐L1) expression has long been used as a biomarker to stratify patients with cancer who will benefit from anti‐PD‐1/PD‐L1 immunotherapy. However, the use of PD‐L1 as a biomarker to guide treatment decisions has recently been called into question due to its dynamic and het...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325512/ https://www.ncbi.nlm.nih.gov/pubmed/35575054 http://dx.doi.org/10.1002/jcb.30273 |